Javier San Martin
Chief Tech/Sci/R&D Officer presso ATHIRA PHARMA, INC.
Patrimonio netto: 6 M $ in data 31/03/2024
Profilo
Attualmente, Javier San Martin è Chief Medical Officer presso Arrowhead Pharmaceuticals, Inc. In precedenza ha ricoperto la posizione di direttore esecutivo dell'area terapeutica dell'osso presso Amgen, Inc, Principal presso Eli Lilly & Co, Senior VP-Global Clinical Development presso Ultragenyx Pharmaceutical, Inc e Senior Vice President-Clinical Development presso Alder Biopharmaceuticals, Inc. Ha ricevuto un dottorato dalla Universidad de Buenos Aires.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 10/01/2024 | 198 497 ( 0.16% ) | 6 M $ | 31/03/2024 |
Posizioni attive di Javier San Martin
| Società | Posizione | Inizio |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Tech/Sci/R&D Officer | 15/04/2024 |
Precedenti posizioni note di Javier San Martin
| Società | Posizione | Fine |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/11/2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Javier San Martin
| University of Buenos Aires School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Borsa valori
- Insiders
- Javier San Martin
